Eureka Therapeutics Announces Data Presentations Validating its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting
–NEW DATA FROM MULTIPLE CAR-T PROGRAMS IN MULTIPLE MYELOMA UTILIZING EUREKA’S BINDING DOMAINS –BCMA/MULTIPLE MYELOMA CAR-T PROGRAM LICENSED TO JUNO THERAPEUTICS (NOW CELGENE) –UPDATED DATA